Indoco Remedies Limited has announced an earnings conference call to discuss its Q3FY26 unaudited financial results. The pharmaceutical company informed both National Stock Exchange of India Limited and Bombay Stock Exchange Limited about the scheduled call through a regulatory filing dated January 20, 2026.

Conference Call Details

The earnings conference call is scheduled to take place on Tuesday, February 3, 2026, at 3:30 PM IST. The call will focus on discussing the company's unaudited financial results for the quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature key members of Indoco Remedies' senior management team who will present the financial results and address investor queries.

Access Information

Nirmal Bang Institutional Equities is hosting the conference call and has provided multiple access options for participants. The call offers both domestic and international dial-in numbers, along with an Express Join feature through DiamondPass for immediate access without waiting time.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Head Legal Ramanathan Hariharan signed the regulatory filing, ensuring compliance with stock exchange notification requirements.

The conference call represents Indoco Remedies' commitment to maintaining transparent communication with investors and stakeholders regarding its financial performance for the third quarter of fiscal year 2026.

In a significant development for Indoco Remedies , the Kare Family Private Trust has completed a substantial share acquisition through off-market transfers dated December 26, 2025. The transaction, executed as part of family succession planning, involved the transfer of shares from Aruna Suresh Kare to the trust without any monetary consideration.

Transaction Details

The regulatory disclosure filed on December 30, 2025, reveals the completion of a major intra-promoter share transfer. The Kare Family Private Trust acquired 55.34 lakh shares representing 6.00% of Indoco Remedies' total share capital from Aruna Suresh Kare through off-market transfer.

Current Shareholding Pattern

Following the completion of this transaction, the Kare Family Private Trust now holds a consolidated position in Indoco Remedies. The trust's shareholding structure demonstrates a strategic consolidation of family assets.

Family Trust Structure

The Kare Family Private Trust was established on November 22, 2024, specifically for smooth succession planning and streamlining family assets and businesses. The trust structure includes Suresh Govind Kare and Aruna Suresh Kare as settlors, while Aditi Milind Panandikar and Madhura Suresh Kare serve as beneficiaries. All parties involved are existing promoters of Indoco Remedies.

Regulatory Compliance

The transaction has been executed in full compliance with SEBI regulations, with appropriate disclosures made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company's equity share capital remains unchanged at ₹18.45 crores, divided into 9.22 crore equity shares of ₹2 each.

Market Impact

This intra-promoter transfer represents a private family arrangement and does not alter the overall promoter shareholding percentage in Indoco Remedies. The transaction strengthens the family's succession planning framework while maintaining the existing control structure of the pharmaceutical company.